Journal
MOLECULAR THERAPY-ONCOLYTICS
Volume 1, Issue -, Pages -Publisher
CELL PRESS
DOI: 10.1038/mto.2014.2
Keywords
-
Categories
Funding
- Aniwel Graduate School, University of Helsinki
- Oncos Therapeutics Ltd.
- European Research Council
- ASCO Foundation
- HUCH Research Funds (EVO)
- Sigrid Juselius Foundation
- Academy of Finland
- Biocentrum Helsinki
- Biocenter Finland
- Finnish Cancer Organizations
- University of Helsinki
Ask authors/readers for more resources
We evaluated adverse events, biodistribution and shedding of oncolytic vaccinia virus encoding CD40 ligand in two Beagles, in preparation for a phase 1 trial in canine cancer patients. Dog 1 received one dose of vaccinia virus and was euthanized 24 hours afterwards, while dog 2 received virus four times once weekly and was euthanized 7 days after that. Dogs were monitored for adverse events and underwent a detailed postmortem examination. Blood, saliva, urine, feces, and organs were collected for virus detection. Dog 1 had mild fever and lethargy while dog 2 experienced a possible seizure 5.5 hours after first virus administration. Viral DNA declined quickly in the blood after virus administration in both dogs but was still detectable 1 week later by quantitative polymerase chain reaction. Only samples taken directly after virus infusion contained infectious virus. Small amounts of viral DNA, but no infectious virus, were detected in a few saliva and urine samples. Necropsies did not reveal any relevant pathological changes and virus DNA was detected mainly in the spleen. The dogs in the study did not have cancer, and thus adverse events could be more common and viral load higher in dogs with tumors which allow viral amplification.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available